Optimization and statistical evaluation of discriminative dissolution method for bisoprolol immediate-release film coated tablets

Ivana Mitrevska1*, Katerina Brezovska2, Aneta Dimitrovska2, Suzan Memed-Sejfulah1, Sonja Ugarkovic1

1Research & Development, Alkaloid AD, Blvd. Aleksandar Makedonski 12, 1000 Skopje, North Macedonia
2Faculty of Pharmacy, Ss. Cyril and Methodius University, Mother Theresa 47, 1000 Skopje, North Macedonia

Received: January 2020; Accepted: February 2020

Abstract

This study presents optimization of a statistically based approach for setting up the dissolution test conditions for bisoprolol film-coated tablets using multivariate release models as predictive in vivo assessment tools for formulation behaviour. Additionally, the dissolution profiles of three different strengths of bisoprolol film-coated tablets were evaluated. According to the biopharmaceutics classification system, the tested medicinal product belongs to BCS Class I (high solubility, high permeability).

Three dissolution media, including the dissolution medium of choice (pH 1.2) according to the USP monograph for bisoprolol tablets and two apparatus, paddle and basket were applied. The optimal conditions for performing the dissolution test were following: 900 mL of pH 1.2 as dissolution medium, apparatus 2 (paddle) with 75 r/min stirring speed. The quantity of the released active substance was determined using HPLC method.

For a reliable statistical analysis, multivariate methods such as model-dependent approach coupled to multivariate statistics (Weibull), multivariate model-independent approach based on generalized statistical distance (Mahalanobis distance) have been applied for evaluation of dissolution profiles. All applied statistical approaches unequivocally support the underlying similarity of the pairs in different media between different strengths. Moreover, the optimized dissolution method has a discriminatory power to reflect the characteristics of the medicinal product in order to distinguish any changes related to quantitative composition of the formulation.

Keywords: bisoprolol film-coated tablet, dissolution profiles, model-independent multivariate statistical distance, model-dependent multivariate statistical distance

Introduction

Dissolution tests are used for many purposes in the pharmaceutical industry: in the development of new medicinal products, for quality control and, to predict the in vivo performance. The dissolution test is developed for evaluation of in vitro availability of solid pharmaceutical dosage forms and to provide information about the active substance release in function of time. It is required when the absorption of the active substance is necessary for therapeutic effect. Almost every monograph of solid dosage form, in official pharmacopoeias, states the conditions for performing the dissolution test. However, parameters for setting up the dissolution test should be investigated and optimized for current medicinal product

* imickoska@alkaloid.com.mk
formulation (Guidance for industry FDA, 1997; USP 38-NF 33, 2015).

Generally, in the development of dissolution test conditions for immediate release solid oral dosage form, water is used as dissolution medium. Aqueous buffer solutions or diluted hydrochloric acid can also be applied. Surfactants and electrolytes can be added to the medium with the intention of improving the solubility. Paddle is usually used as apparatus for tablets, at the stirring speed of 50 r/min or 75 r/min. Basket is usually used as apparatus for capsules or pharmaceutical forms that tend to float in the dissolution medium. In this case, the usual stirring speed is 100 r/min. The evaluation is accomplished after the end of the test, determined the percent of the active substance release in the dissolution medium (Soni et al., 2008).

The establishment of dissolution profiles is recommended as support in the development phase for determination of in vitro/in vivo correlation. This could be achieved if the conditions in the gastrointestinal tract were successfully reconstructed in vitro. Therefore, brief comments are made concerning the optimization of in vitro dissolution media as well as the hydrodynamics of the test. A combination of physical-chemical measurements, in vitro tests, in vivo methods, and physiology-based pharmacokinetic modelling is expected to create a unique knowledge platform, enabling the bottlenecks in drug development to be removed and the whole process of medicinal product development to become more efficient.

Regarding to the biopharmaceutics classification system (Amidon et al., 1995), the active substance solubility profile in buffer solutions with different pH values, its pKa value and partition coefficient should be considered for setting up the dissolution test conditions (Löbenberg et al., 2000). Comparison of medicinal product dissolution profiles is recommended in three different dissolution media, in the pH range of 1-7.5 (Carvalho-Silva et al., 2004).

Bisoprolol fumarate (Fig. 1) is highly beta 1-selective adrenoreceptor antagonist. The active substance has pKa values of 9.59±0.01 and molecular weight of 441.5 g/mol. The study of its solubility profile in buffer solutions of different pH values indicates that bisoprolol fumarate is a highly soluble active substance. Additionally, pharmacokinetic data regarding absorption and plasma concentration indicate that bisoprolol fumarate is a high permeability active substance (Tjandrawinata et al., 2013, https://pubchem.ncbi.nlm.nih.gov/compound/Bisoprolol-fumarate).

Several methods for evaluation and comparison of the dissolution profiles are described in the literature. Model-dependent methods consider various mathematical models to associate profiles. According to Costa and Lobo release models with major applicability and that best describe active substance release phenomena are Weibull along with Higuchi, zero-order and Korsmeyer-Peppas (Costa et al., 2001).

The aim of this study was to optimize statistically based approach for setting up the dissolution test conditions for bisoprolol film-coated tablets using multivariate release models as predictive in vivo assessment tools for formulation behaviour. Additionally, the dissolution profiles of three different strengths of bisoprolol film-coated tablets were evaluated.

Materials and methods

Reagents, materials and equipment

Bisoprolol film-coated tablets 2.5 mg, 5 mg and 10 mg, bisoprolol fumarate working standard (WS), potassium dihydrogen phosphate and sodium hydroxide were with analytical grade. Dissolution media: pH 1.2 (HCl, NaCl), acetate buffer pH 4.5 and phosphate buffer pH 6.8 were prepared according to directions in European Pharmacopeia monograph (Ph. Eur., 5.17., 2010).

The following instruments were used: six-station dissolution apparatus (Varian-Vankel 7025 Model: 115/230) in accordance with USP general methods, pH meter (Mettler Toledo), hotplate stirrer (IKA C-MAG HS7), analytical balance (Sartorius CPA 225D-OCE). The active substance release percent (DR %) was assayed by HPLC method at the wavelength of 227 nm, in accordance with the United States Pharmacopeia general method (USP-31- NF 26, Vol 3:3526, 2008).

Dissolution tests conditions

The dissolution tests on bisoprolol film-coated tablets were performed using Apparatus I and II at 37±0.5°C, with a rotation speed of 75 r/min for paddle and 100 r/min for basket using 900 mL buffer pH 1.2 as dissolution media. After the end of test time, each sample aliquot was diluted to a suitable concentration and then analyzed by HPLC method.

Maced. pharm. bull., 66 (1) 43 – 53 (2020)
\[ F(t) = 100 \cdot \left[1 - \exp \left(-\frac{t^\beta}{\alpha} \right) \right] \] \hspace{1cm} (2)

Subsequently, the model parameters \( \alpha \) and \( \beta \) have been obtained for all available series of data by non-linear least-squares fitting procedure.

**Results and discussion**

Model-independent methods associate the dissolution assay results of simple ratio percent dissolved active substance (\( t_s \), %) or based on the area under the release curve (AUC) of dissolution profiles, obtained from reference and test products (Shah et al., 1998). The most adopted model-independent methods are the difference factor (\( f_1 \)) and the similarity factor (\( f_2 \)). Unfortunately, the obtained results have shown that in vitro comparative dissolution analysis using pair-wise independent-model procedures, such as difference (\( f_1 \)) and similarity (\( f_2 \)) factors are not suitable, because one of the requirements (not more than one mean value dissolves more than 85\%, for any of the formulations) was not fulfilled (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr., 2010).

Starting from all these considerations, this work was divided in two parts. The first concerning the dissolution test set up, using buffer pH 1.2 as dissolution media, two apparatus and different rotating speed. The second part implicated in the use of the optimized dissolution test condition, obtained in the first part, to evaluate dissolution profiles of three different dosage strengths of the medicinal product.

The dissolution efficiency was calculated and all the results were statistically compared. If the comparisons of these profiles demonstrated similarity between different product dosage strengths, in vivo bioequivalence testing can be waived.

**pKa**

The active substance pKa value was determined using the potentiometric titration method. Thus, 0.01 M phosphate buffer was used to prepare the sample solution, and pH of the buffer were accurately adjusted from pH 1.9 to 11.2 with 0.2 interval using 0.5 M HCl and 0.5 M KOH titrants as appropriate.

Form the obtained data, one pKa with an average value of 9.59±0.01 was observed (Fig. 2).

**Solubility**

The sample intrinsic and kinetic solubility were determined using the Sirius Curve fitting solubility experiment. The sample solution was titrated from pH 4.4 to high pH with 0.5 M KOH. At a pH of 9.12, the sample precipitated from solution, as detected by a UV-turbidity
probe, corresponding to a kinetic solubility of 56 mM (18 mg/mL). After precipitation, the pH gradient was monitored after each addition of KOH and the pH was recorded when d(pH)/dt(t) had tended to zero (i.e. where the solid and solution are at equilibrium). The precipitate Bjerrum curve thus obtained was used to calculate the sample intrinsic aqueous solubility (46.9 mM) using mass and charge balance equations. It should be noted that as the kinetic and intrinsic solubility of this compound are similar, this compound is not capable of forming significantly supersaturated solutions under the experimental conditions of this investigation (Avdeef et al., 1982).

The sample solubility was also determined in buffer pH 1.2, using a shake-flask protocol with sample quantification by UV-spectroscopy. To enable sample quantification, the molar extinction coefficients of bisoprolol fumarate were measured at a sample concentration of 50 μM in pH 1.2. To determine the solubility, 3.0 mL of buffer pH 1.2 was added to 7.2 g of pure bisoprolol fumarate, producing a suspension that was subsequently agitated for 12 hours on an electronic shake-plate. After agitation, the sample was left for a sedimentation period of 12 hours before an aliquot of the supernatant solution was extracted by pipette, filtered under vacuum through a 0.2 μm PVDF filter plate, and its absorption spectrum recorded in pH 1.2 (diluted by a factor of 10000). The solubility was subsequently determined as 2182 mM (1674 mg/ml) from the measured absorption of the supernatant solution (over a wavelength range of 250 nm-270 nm), the experimental dilution factor, and the previously determined molar extinction coefficients (Fig. 3).

**Dissolution test results**

Optimization of the method included selection of suitable stirring speed in order to obtain dissolution method with required performance, providing data that are not highly variable and to avoid coning or mounding problems. On 50 r/min conning was noticed which lead to incomplete release of active substance from tablets and risk for obtaining variable results. On the other hand, when compared paddle (75 r/min) vs. basket (100 r/min) similar profile of active substance release was observed. Dissolution was evaluated by measuring the amount dissolved over time and carried out on twelve (12) tablets. The obtained results are presented in Table 1. The dissolution profile of bisoprolol 10 mg film-coated tablets is shown on Fig. 4.

The results from evaluation of dissolution profile using pH 1.2 as dissolution medium and paddle or basket as apparatus at the stirring speed of 75 r/min, the show no evident difference. According to the results represented in Fig. 4, it could be presumed that basket as apparatus at stirring speed of 100 r/min is equivalent to paddle as apparatus at the stirring speed of 50 r/min.
The discriminatory power of the proposed dissolution method was confirmed by comparing the dissolution profiles for the two different formulations of Bisoprolol film-coated tablets in buffer pH 1.2 with paddle 75 r/min: original formulation and formulation with Hypromellose K (coating excipient) vs. proposed formulation with Hypromellose K 15 Premium K (coating excipient). Results have shown substantial differences in the dissolution profiles of the given formulations (Fig. 5).

Results reveal that inclusion of Hypromellose K 15 Premium in the formulation decreased the percent of dissolved substance from cca 100% (proposed formulation) down to cca 18% after 20 minutes. According to the above statement, the investigated dissolution conditions provide a method that is discriminating.
Table 1. The obtained results of dissolution test of bisoprolol 10 mg film-coated tablets using different apparatus and rotating speed

| Medium pH 1.2          | Bisoprolol 10 mg film-coated tbl. paddle, 75 r/min, 900 mL | Bisoprolol 10 mg film-coated tbl. paddle, 50 r/min, 900 mL | Bisoprolol 10 mg film-coated tbl. basket, 100 r/min, 900 mL |
|------------------------|------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| Time                   | 10’ 15’ 20’ 30’                                           | 10’ 15’ 20’ 30’                                          | 10’ 15’ 20’ 30’                                          |
| min. =                 | 92.66 92.63 93.15 93.44                                   | 33.87 42.31 45.74 57.16                                 | 90.38 90.04 89.92 89.75                                  |
| max. =                 | 105.67 100.85 100.50 99.36                                 | 90.52 94.82 93.96 96.47                                 | 101.95 101.10 101.27 101.19                              |
| Average =              | 98.68 97.04 96.49 96.22                                   | 74.49 81.27 84.30 88.41                                 | 96.04 95.67 95.59 95.35                                  |
| SD =                   | 3.15 2.38 2.15 1.83                                       | 15.44 13.92 13.07 10.41                                 | 3.65 3.54 3.50 3.50                                     |
| % RSD =                | 3.19 2.45 2.23 1.91                                       | 120.7 11.7 11.7 11.7                                     | 120.7 11.7 11.7 11.7                                    |

Comparative dissolution data

In order to confirm the applicability of the proposed dissolution method for all the strengths of bisoprolol film-coated tablets (2.5 mg, 5 mg and 10 mg), the dissolution profiles in 900 mL buffer pH 1.2 with paddle rotation speed of 75 r/min were compared. Results of performed comparative dissolution study are provided in Table 2 and Fig. 6. The procedures have been performed in a standard apparatus 2 with paddle at rotation speed of 75 r/min in 900 mL of above-described medium. The dissolution rate of bisoprolol fumarate has been determined using HPLC method. Similarity have been justified by dissolution profiles covering four time points obtained at specified medium buffer pH 1.2, 4.5 and 6.8. Evaluation of the dissolution profile in three different mediums was done on:

- Bisoprolol 10 mg film-coated tablet vs. Bisoprolol 2.5 mg film-coated tablet

The results obtained from all generated profiles, more than one mean value above 85% for any of the tested batches is observed at 15 minutes, creating a consequence that the $f_2$ statistics for determining profile similarity is not applicable. In accordance to the guideline (EMA, Guideline on the investigation of bioequivalence, 2010) in such cases alternative statistical methodologies can be employed for demonstrating dissolution similarity. Therefore, in order to provide a more accurate, statistically justified conclusion, analysis on the basis of model-independent method based on generalized statistical distance and model-dependent method, coupled to multivariate statistical approach were accomplished.

A multivariate confidence region procedure, based on 90% confidence intervals of the generalized statistical distance between the variables is carried out.

![Dissolution profile of bisoprolol 2.5, 5 and 10 mg film-coated tablets with a change in the type of excipients (mis-manufactured).](image-url)

Maced. pharm. bull., 66 (1) 43 – 53 (2020)
Fig. 6. *In vitro* dissolution profiles of different strengths of bisoprolol film-coated tablets: a) in medium pH 1.2, b) in medium pH 4.5, c) in medium pH 6.8.

Макед. фарм. булт., 66 (1) 43 – 53 (2020)
### Table 2. *In vitro* dissolution profiles of different strengths of the medicinal products

#### Table 2a. *In vitro* dissolution profiles of different strengths of the medicinal products in medium pH 1.2

| Time | Bisoprolol 10 mg film-coated tbl. | Bisoprolol 5 mg film-coated tbl. | Bisoprolol 2.5 mg film-coated tbl. |
|------|----------------------------------|----------------------------------|----------------------------------|
| min. | 75.89                            | 84.17                            | 92.01                            |
| max. | 94.94                            | 97.17                            | 100.33                           |
| Average | 85.93                             | 89.70                            | 91.90                            |
| SD   | 5.56                             | 4.33                             | 3.69                             |
| %RSD | 6.47                             | 4.83                             | 4.01                             |

#### Table 2b. *In vitro* dissolution profiles of different strengths of the medicinal products in medium pH 4.5

| Time | Bisoprolol 10 mg film-coated tbl. | Bisoprolol 5 mg film-coated tbl. | Bisoprolol 2.5 mg film-coated tbl. |
|------|----------------------------------|----------------------------------|----------------------------------|
| min. | 71.15                            | 80.87                            | 79.96                            |
| max. | 100.54                           | 100.49                           | 98.56                            |
| Average | 84.55                            | 88.82                            | 89.80                            |
| SD   | 8.70                             | 5.21                             | 5.20                             |
| %RSD | 10.29                            | 5.87                             | 5.79                             |

#### Table 2c. *In vitro* dissolution profiles of different strengths of the medicinal products in medium pH 6.8

| Time | Bisoprolol 10 mg film-coated tbl. | Bisoprolol 5 mg film-coated tbl. | Bisoprolol 2.5 mg film-coated tbl. |
|------|----------------------------------|----------------------------------|----------------------------------|
| min. | 75.89                            | 84.17                            | 92.01                            |
| max. | 94.94                            | 97.17                            | 100.33                           |
| Average | 85.93                            | 89.70                            | 91.90                            |
| SD   | 5.56                             | 4.33                             | 3.69                             |
| %RSD | 6.47                             | 4.83                             | 4.01                             |
Table 3. Mahalanobis distance between 10 mg vs. 5mg and 2.5mg film-coated

|   | K  | F(p,n1+ n2-p-1,0.90) | DM  | 90 % CI-low | 90 % CI-high | DM_{max} |
|---|-----|----------------------|-----|--------------|--------------|----------|
|   |     |                      |     |              |              |          |
| pH 1.2 | 5 mg | 1.2955               | 2.2663 | 1.3523       | 0.0296       | 2.6749   | 3.5588   |
|   | 2.5 mg | 1.2955               | 2.2663 | 1.1128       | -0.2099      | 2.4355   | 3.7819   |
| pH 4.5 | 5 mg | 1.2955               | 2.2663 | 1.2020       | -0.1206      | 2.5247   | 2.4069   |
|   | 2.5 mg | 1.2955               | 2.2663 | 1.4430       | 0.1203       | 2.7656   | 2.0141   |
| pH 6.8 | 5 mg | 1.2955               | 2.2663 | 3.2779       | 1.9552       | 4.6006   | 3.9548   |
|   | 2.5 mg | 1.2955               | 2.2663 | 1.8335       | 0.5108       | 3.1561   | 2.8107   |

Table 4. Two-parameter Weibull model function – logarithmic (ln) transformation of data for fitting parameters between different strengths of the medicinal product

|   | K  | F(p,n1+ n2-p-1,0.90) | DM  | 90 % CI-low | 90 % CI-high | DM_{max} |
|---|-----|----------------------|-----|--------------|--------------|----------|
|   |     |                      |     |              |              |          |
| pH 1.2 | 5 mg | 2.7329               | 2.5893 | 1.2010       | 0.2276       | 2.1744   | 18.4107  |
|   | 2.5 mg | 2.7329               | 2.5893 | 0.7649       | -0.2084      | 1.7383   | 18.4107  |
| pH 4.5 | 5 mg | 2.7329               | 2.5893 | 0.4218       | -0.5264      | 1.3700   | 6.5615   |
|   | 2.5 mg | 2.7329               | 2.5893 | 0.4879       | -0.4603      | 1.4361   | 6.5615   |
| pH 6.8 | 5 mg | 2.7329               | 2.5893 | 2.2932       | 1.3199       | 2.6153   | 3.3603   |
|   | 2.5 mg | 2.7329               | 2.5893 | 1.6420       | 0.6686       | 2.6153   | 3.3603   |
The method that is actually adopted in the present study closely follows the approach derived by Tsong et al. (1996). These authors have described a multivariate method that uses the Mahalanobis distance as a particular generalized statistical distance parameter, which takes the variability and correlation structure into account in measuring the difference between mean dissolution profiles (Table 3).

The decisions of similarity can be made with appropriate comparison of the confidence limits of the estimated metric with a prespecified similarity limit $DM_{max}$. The 90% confidence limits of $DM$ can be obtained from the multivariate confidence region of the expected values of $x_{test}$ and $x_{ref}$ (the sample means), under multivariate normal assumption. When looking at the results from the performed multivariate method, it is obvious that these dissolution profiles can be considered as similar.

Additionally, for the purpose of the present study model-dependent approach function based on generalized statistical distance was applied. The first step of the model-dependent analysis involved selection of a suitable mathematical function to describe the dissolution data. Considering the higher determination coefficient, the preferred model that fits best to the dissolution data between strengths was the Weibull distribution model. The Weibull shape parameter, $\beta$, showed no significant variation ($\beta>1$). The results of the Weibull-multivariate statistical test are presented in Table 4.

**Conclusion**

The dissolution profiles of three different strengths of bisoprolol film-coated tablets were evaluated using optimized statistical approach based on multivariate release models. All applied statistical approaches unequivocally support the underlying similarity of the pairs in different media between different strengths. The preferred model that fits best to the dissolution data between strengths was the Weibull distribution model. The optimized dissolution method has a discriminatory power to reflect the characteristics of the medicinal product in order to distinguish any changes related to quantitative composition of the formulation.

The discriminating multivariate statistical approach, described in this paper, provides extra arguments when deciding if two profiles are similar, as it allows a better description of the dissolution process (i.e., rate and amount dissolved) and thus a better prediction of in vivo performance. According to these simulations, the established approach can be used to waive in vivo bioequivalence testing between different strengths form the medicinal product.

**References**

Amidon, G., Lennernas, L.H., Shah, V.P., Crison, J.R., 1995. A Theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research 12(3), 413-420. Available at: https://doi.org/10.1023/a:1016212804288.

Avdeef, A., Kearny, L.D., Brown, A.J., Chemotti, R.A., 1982. Bjerrum plots for the determination of systematic concentration errors in titration data. Analytical chemistry 54(13), 2322-2326. Available at: https://doi.org/10.1021/ac00250a041.

Carvalho-Silva, B., Moreira-Campos, L.M., Nunan, E.A., Vianna-Soares, C.D., Araujo-Alves, B.L., Cesar, I.C., Pianetti, G.A., 2004. Optimization and statistical evaluation of dissolution tests for indinavir sulfate capsules. II farmaco 59 (11), 921-927. Available at: https://doi.org/10.1016/j.farmac.2004.08.001.

Costa, P., Lobo, J.M.S., 2001. Modelling and comparison of dissolution profiles. European Journal of Pharmaceutical Science 13(2), 123-133. Available at: https://doi.org/10.1016/S0928-0977(01)00095-1.

Costa, P., 2001. An alternative method to the evaluation of similarity factor in dissolution testing. International Journal of Pharmaceuticals 220(1-2), 77-83. Available at: https://doi.org/10.1016/s0378-5173(01)00651-2.

European Pharmacopoeia 9th edition. Recommendations on dissolution testing 5.17.1.07/2010:51701(762).

European Medicines Agency, EMA 2010. Guideline on the investigation of bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1/ Corr). Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf

Dressman, J.B., Amidon, G.L., Reppas, C., Shah, V.P., 1998. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharmaceutical Research 15(1), 11–22. Available at: https://doi.org/10.1023/a:1011984216775.

Gohel, M. C., Panchal, M. K., 2010. Comparison of in vitro dissolution profiles using a novel, model-independent approach. American Association of Pharmaceutical Scientists 12(3), 263–271.

Guidance for industry, FDA (CDER), 1997. Dissolution Testing of Immediate Release Solid Oral Dosage Forms, US Department of Health and Human Services. Available at: http://www.fda.gov/cder/guidance.htm.

Löbenberg, R., Amidon, G.L., 2000. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. European Journal of Pharmaceutics and Biopharmaceutics 50(1), 3-12. Available at: https://doi.org/10.1016/s0939-6411(00)00091-6.

Pillay, V., Fassihi R., 1998. Evaluation and comparison of dissolution data derived from different modified release dosage forms: an alternative method. Journal of Control Release 55(1), 45-55. Available at: Maced. pharm. bull., 66 (1) 43 – 53 (2020)
Резиме

Општо: На овој труд прикажана е оптимизација на статистички базиран пристап за воспоставување на услови за изведба на тестот за растворливост на бисопролол филм-обложени таблети. Во согласност со Конвенционалност на растворливоста на бисопролол филм
обложени таблети, испитувањата се изведени со примена на USP монографија за бисопролол таблети, а испитуваните леку припаѓаат на класа BCS I (висока независност). Испитуването е извршено со примена на три медиуми за растворливост, вклучително и медиум со pH 1,2, што е претставено како медиум од избор во USP монографијата за бисопролол таблети и со примена на два апарати за растворливост, веќе и корпа. Како оптимални услови за изведба на тестот за растворливост избран области следните услови: 900 mL медиум за растворливост pH 1,2, апарат 2 (весло) со брзина на вртење 75 вртежи во минути. Содржината на ослободената активна с
не се определена со примена на HPLC метод.

Евалуацијата на профилите на растворливост е извршена со примена на статистичка анализа базирана на статистички модел-независна мултиваријатна статистика. Во овој труд прикажана е оптимизација на статистички базиран пристап за воспоставување на услови за
опредељување на растворливоста на бисопролол филм-обложени таблети со примена на мултиваријатни модели за предвидување на карактеристиките на формулацијата во in vivo услови. Дополнително, евалураа се и профилите на растворливост за трите различни жакини од бисопролол филм-обложените таблети. Во согласност со „Биофармацевтски систем за класификација” (BCS), испитуванот метод лек припажа на BCS класа I (висока растворливост, висока пермабилност).

Испитуването е извршено со примена на три медиуми за растворливост, вклучително и среду со pH 1,2, што е претставено како медиум од избор во USP монографијата за бисопролол таблети и со примена на два апарати за растворливост, велос и корпа. Како оптимални услови за изведба на тестот за растворливост избране се следните услови: 900 mL медиум за растворливост pH 1,2, апарат 2 (весло) со брзина на вртење 75 вртежи во минута. Содржината на ослободената активна с
не се определена со примена на HPLC метод.

Евалуацијата на профилите на растворливост е извршена со примена на статистичка анализа базирана на статистички модел-независна мултиваријатен методи како што се: модел-независност пристап во комбинација со мултиваријантна статистика (Weibull) и модел-независности метод заснован на генерализирани статистички растојание (Mahalanobis distance). Сите применети статистички пристапи недоносило да поддржуваат сличноста на споредените парови во испитуваните медиуми помеѓу различните жакини на лекот. Оптимизиранот метод за растворливост поседува дискриминарна моќ да ги претстави карактеристиките на медицинскиот производ и да ги детектира евентуалните промени поврзани со квантитативниот состав во формулацијата.

Макед. фарм. биог., 66 (1) 43 – 53 (2020)
